A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

2/3

Condition

Asthma

Treatment

N/A

Clinical Study ID

TX208027
  • Ages 18-80
  • All Genders

Study Summary

Primary Objective: To assess the effect of 3 doses of GP MDI compared to Placebo MDI and Spiriva® Respimat® on lung function over 24 weeks in subjects with persistent asthma.

Eligibility Criteria

Inclusion

  • Pre-bronchodilator FEV1 >40% and <85%
  • Body mass index <40 kg/m2
  • Require inhaled asthma maintenance therapy: has been regularly using an ICS/LABA

Study Design

Study Start date:
Estimated Completion Date:

Study Description

If patients qualify, all study procedures including lab work, tests, study visits, and the study drug are provided to you free of charge by the sponsor.